PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...

PathAI: Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs  SECAUCUS, N.J. and BOSTON –...